Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
|ClinicalTrials.gov Identifier: NCT01650766|
Recruitment Status : Unknown
Verified July 2012 by Xu jianming, The Affiliated Hospital of the Chinese Academy of Military Medical Sciences.
Recruitment status was: Recruiting
First Posted : July 26, 2012
Last Update Posted : July 26, 2012
|Condition or disease|
TS, DPD and OPRT are the key enzymes on the metabolic pathway of 5-Fu. We will retrospectively analyze the clinicopathological features of the patients who have suffered an inoperative or recurrent gastric cancers and administrated with S-1, such as the overall survival (OS), progressive-free survival (PFS), Lauren's classification and toxicity of S1, etc. We will divide the patients into several subgroups according to the parameters above, and then investigate the correlation between the parameters and the expression of TS, DPD and OPRT.
All of the analysis is retrospective, there is no different treatment operation once the subject enrolled in this study.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers|
|Study Start Date :||February 2012|
|Estimated Study Completion Date :||October 2012|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01650766
|307 Hospital of PLA||Recruiting|
|Beijing, Beijing, China, 100071|
|Contact: Xu Jianming, M.D. +861051168358 firstname.lastname@example.org|
|Principal Investigator:||Xu Jianming, M.D.||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|